THCV, or tetrahydrocannabivarin may have the potential to help with energy, focus/attention, and even appetite, weight/BMI, according to InMed Pharmaceuticals Inc.’s (NASDAQ: INM).
In addition, according to LAweekly.com, THCV benefits are reported to be pretty incredible, including but not limited to: Easing and reducing panic attacks, Appetite suppression and weight loss aid, Blood sugar regulation, Reducing muscular tremors and neuroprotection, Bone protection and growth, and relaxation.
“Neuroprotectants like THCV protect the neurological function of the brain by strengthening neural pathways and neurons, while stimulating neurogenesis, which is the birth of new neurons to keep brain functionality efficient. Neuroprotectants are particularly of interest to those researching Alzheimer’s and dementia, as these disorders are directly impacted by a loss of neurons and a weakening of neural pathways,” they added. In addition to InMed Pharmaceuticals, companies such as
Tilray Inc. (NASDAQ: TLRY) (TSX: TLRY), Canopy Growth (TSX: WEED) (NASDAQ: CGC), Jazz Pharmaceuticals (NASDAQ: JAZZ), and AbbVie Inc. (NYSE: ABBV) could benefit from the news.